FDA Approves Oral Topotecan for Relapsed Small-Cell Lung Cancer

Publication
Article
OncologyONCOLOGY Vol 21 No 12
Volume 21
Issue 12

FDA Approves Oral Topotecan for Relapsed Small-Cell Lung Cancer

The US Food and Drug Administration (FDA) has approved oral topotecan (Hycamtin) capsules for the treatment of relapsed small-cell lung cancer (SCLC). Topotecan capsules are indicated for patients who had a complete or partial response to first-line chemotherapy and who are at least 45 days from the end of that treatment. Topotecan capsules are the only oral single-agent chemotherapy approved for the treatment of SCLC after failure of first-line therapy. The product will be available in 2008.

Articles in this issue
Ixabepilone Approved for the Treatment of Advanced Breast Cancer
Positive Results Announced From Pivotal Study of Bendamustine in Non-Hodgkin's Lymphoma
ASCO/ASH Release Updated Guidelines on Chemotherapy-Related Anemia Treatments
Spending More for Lung Cancer Treatment Did Not Substantially Increase Patients' Lives
FDA Approves Oral Topotecan for Relapsed Small-Cell Lung Cancer
Temsirolimus Improves Survival in Renal Cell Carcinoma Patients
Breast MRI: The Radiologist's Perspective
Continued Progress in Treatment Options for Multiple Myeloma: From Past to Present and Future
Dermatologic Issues in Cancer Patients: Review of a Review
The Three Most Common Chemotherapy-Related Skin Reactions
Anthracyclines Survive Targeted Therapy
Reducing the Burden of Cancer
Prostate Cancer, PSA, and Questions That Can Only Be Answered By Clinical Trials
Biochemical Failure in Prostate Cancer: Managing Patients with Limited Data
Liposomal Doxorubicin in Combination With Bortezomib for Relapsed or Refractory Multiple Myeloma
Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content
The blood-based test detected 31% of lung cancers 1 year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Blood-Based Screening Test May Increase Preclinical Lung Cancer Detection

Roman Fabbricatore
November 22nd 2025
Article

The blood-based test detected 31% of lung cancers one year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts

Russ Conroy
November 11th 2025
Article

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Ariana Pelosci
November 8th 2025
Article

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.